Cargando…

PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment

Detalles Bibliográficos
Autores principales:	Li, Jing, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292449/ http://dx.doi.org/10.1186/2051-1426-2-S3-P221

Ejemplares similares

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Negative regulation of the SH2-homology-containing protein-tyrosine phosphatase-1 (Shp-1) P2 promoter by the HTLV-1 tax oncoprotein
por: Cheng, Jihua, et al.
Publicado: (2006)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps–SHP-2 pathway
por: Xu, Sheng, et al.
Publicado: (2012)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway
por: Luz-Crawford, Patricia, et al.
Publicado: (2012)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
por: Rice, Adrian E, et al.
Publicado: (2015)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

The association of autoantibodies expression, Th1/Th2 cytokines balance and IFNG polymorphism with histological phenotype of lupusnephritis
por: Handono, Kusworini, et al.
Publicado: (2012)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
por: Toral, Keller J., et al.
Publicado: (2021)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
por: Ghebeh, Hazem, et al.
Publicado: (2015)

Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin
por: Hayakawa, Taeko, et al.
Publicado: (2014)

SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
por: Liu, Zhuqing, et al.
Publicado: (2017)

Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells
por: Rekoske, Brian, et al.
Publicado: (2013)

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Transduction of human dendritic cells with adenovirus encoding anti-PD-1 reduces PD-1 expression on co-cultured T cells
por: Patricia, Santos, et al.
Publicado: (2014)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lq8rli4hv6ptl2ijahj8oitjb7